Dr. Dana Feigenbaum, M.D.
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Medical school
- University of California, San Diego School of Medicine (2015)
- Years since graduation
- 11
- In the NPI registry since
- 2015
- Medicare patients seen, 2024
- 288
Licensed in California since 2017, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2015Medical school: University of California, San Diego School of Medicine
- 2015Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
CA license A146836 (first issued 2017; current) - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- UCSF Medical Center San Francisco, CA
Medical groups
- Regents of the University of California - UCSF (80 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 288
- Services billed
- 1,229
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 454 | 94 |
| Established patient office or other outpatient visit, 20-29 minutes | 217 | 160 |
| Destruction of precancer skin growth, 1 growth | 170 | 127 |
| Established patient office or other outpatient visit, 30-39 minutes | 117 | 98 |
| Destruction of skin growth, 1-14 growths | 108 | 93 |
| Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | 53 | 38 |
| Biopsy of related skin growth, first growth | 49 | 43 |
| Application of light with debridement to destroy precancer skin growth | 48 | 37 |
| New patient office or other outpatient visit, 30-44 minutes | 47 | 47 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 27 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 15 companies reported 50 payments worth $1,261 in total to this clinician.
| Incyte Corporation | $261 |
|---|---|
| AbbVie Inc. | $216 |
| Arcutis Biotherapeutics, Inc. | $215 |
| Lilly USA, LLC | $80.34 |
| Pfizer Inc. | $76.27 |
| Organon LLC | $72.80 |
| Galderma Laboratories, L.P. | $65.06 |
| Sun Pharmaceutical Industries Inc. | $61.02 |
| Food and Beverage | $1,261 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.